688192 Stock Overview
Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥37.54 |
| 52 Week High | CN¥54.58 |
| 52 Week Low | CN¥24.82 |
| Beta | 0.16 |
| 11 Month Change | -5.80% |
| 3 Month Change | -10.79% |
| 1 Year Change | 16.37% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -8.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688192 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 5.4% | 0.4% | -0.6% |
| 1Y | 16.4% | -24.5% | -21.3% |
Return vs Industry: 688192 exceeded the CN Biotechs industry which returned -24.5% over the past year.
Return vs Market: 688192 exceeded the CN Market which returned -21.3% over the past year.
Price Volatility
| 688192 volatility | |
|---|---|
| 688192 Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 688192 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688192's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 581 | Zhang Xiaolin | www.dizalpharma.com |
Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical trials for the treatment of solid tumors. The company was founded in 2017 and is based in Shanghai, China.
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Fundamentals Summary
| 688192 fundamental statistics | |
|---|---|
| Market cap | CN¥15.60b |
| Earnings (TTM) | -CN¥1.09b |
| Revenue (TTM) | CN¥172.61m |
90.4x
P/S Ratio-14.3x
P/E RatioIs 688192 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688192 income statement (TTM) | |
|---|---|
| Revenue | CN¥172.61m |
| Cost of Revenue | CN¥9.72m |
| Gross Profit | CN¥162.89m |
| Other Expenses | CN¥1.26b |
| Earnings | -CN¥1.09b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.63 |
| Gross Margin | 94.37% |
| Net Profit Margin | -632.90% |
| Debt/Equity Ratio | 74.9% |
How did 688192 perform over the long term?
See historical performance and comparison